David Darling has a dig at DHB delays

David Darling has a dig at DHB delays
David Darling: Disappointed with slow adoption (Image: Supplied)
Brent Melville
Pacific Edge’s cancer diagnostic products have made headway into the US healthcare sector over the past several years, but many New Zealand patients continue to be shut out by the bureaucracy of local DHBs, the company says.Last June, the NZX-listed firm announced giant US healthcare group Kaiser Permanente had approved its Cxbladder products for use by urologists to monitor patients for bladder cancer. A month later it announced Cxbladder tests will be covered by the Centers for Medicare and Medicaid Services (CMS) across the US mar...

More Markets

Fletcher’s down 3.6%; NZX misses ceasefire rally
Markets Market Close

Fletcher’s down 3.6%; NZX misses ceasefire rally

 Channel Infrastructure has benefited from tensions in the Middle East, an analyst said.

Fletcher's restructuring, impairment costs could hit $781m
Infrastructure

Fletcher's restructuring, impairment costs could hit $781m

It expects ebit of $370m to $375m before significant items. 

Tait wants Vital to fast-track growth
Markets

Tait wants Vital to fast-track growth

If successful, Tait Communications will pay $18.7m to take the listed firm private.

Selling Kiwifruit at Beijing’s $5b-a-year department store
Primary Sector

Selling Kiwifruit at Beijing’s $5b-a-year department store

Turns out the personal touch helps sell kiwifruit at a high-end Chinese supermarket.